オプションチェーンは、H2O Retailingの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、H2O Retailingの市場センチメントを評価します。.

H2O Retailing (OTC:HTOCF) 株価情報, オプションチェーン

H2O Retailing Corp is a Japan-based retailer that provides a broad range of merchandise to meet consumers' needs, from daily needs to special products. The company's core business is the department store business, which includes both the Hankyu and Hanshin department store chains. Superstore business is the company's another major business arm, including the Izumiya and Hankyu Oasis store chains. H2O Retailing also runs a specialty store business, engaged in providing cosmetics, ladies' footwear, and other products and services. In addition to retail businesses, the company operates other businesses as well, such as hotels and restaurants.

H2O RETAILING CORP. ORDIN by H2O Retailing Corp.

H2O Retailing Corp

Snowflake Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/05/b45552044/snowflake-reports-financial-results-for-the-first-quarter-of-fiscal-2026">from the quarter</a>.
Q1 Earnings: Snowflake reported first-quarter revenue of $1.04 billion, beating analyst <a href="http://benzinga.com/quote/SNOW/earnings">estimates</a> of $1.01 billion.&nbsp;The AI data cloud company reported adjusted earnings of 24 cents&nbsp;per share, beating analyst estimates of 21 cents&nbsp;per share, according to <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up 26% year-over-year. Product revenue came in at $996.8 million, also up 26% year-over-year. Net revenue retention rate was 124% in the quarter.&nbsp;
Remaining performance obligations totaled $6.7 billion, up 34% year-over-year. Snowflake said it ended the quarter with 606 customers with trailing 12-month product revenue greater than $1 million. The company also had approximately $2.24 billion in cash and cash equivalents at quarter&#8217;s end.
&#8220;Snowflake&#8217;s mission is to empower every enterprise to achieve its full potential through data and AI,&#8221; said&nbsp;Sridhar Ramaswamy,&nbsp;CEO of Snowflake.
&#8220;Our focus on making the Snowflake platform easy to use, to enable fluid access to data wherever it sits, and trusted for enterprise-grade performance, is what makes us differentiated and beloved by more than 11,000 customers. We see an enormous opportunity ahead as we extend this value throughout the full data lifecycle.&#8221;
Guidance:&nbsp;Snowflake&nbsp;expects second-quarter product revenue in the range of $1.035 billion to $1.04 billion,&nbsp;up approximately 25% year-over-year. The company anticipates full-year product revenue of $4.33 billion, representing 25% year-over-year growth.
Snowflake executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
SNOW Price Action: <a href="http://benzinga.com/quote/SNOW">Snowflake shares</a> were up approximately 17% year-to-date heading into the print. The stock was up 7.41% in after-hours, trading at $192 at the time of publication on Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45550440/snowflake-melts-resistance-can-q1-earnings-spark-a-fresh-flurry-of-gains">Snowflake Melts Resistance: Can Q1 Earnings Spark A Fresh Flurry Of Gains?</a></li>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45550679/treasury-yields-top-5-these-20-stocks-tanked-in-just-one-hour">Treasury Yields Top 5%: These 20 Stocks Tanked In Just One Hour</a></li>
</ul>
Photo: Shutterstock.

Earnings

News

Guidance

Movers

SNOW

Snowflake Q1 Earnings: Revenue, EPS Beat Estimates, AI Data Cloud Company Sees 25% Growth Ahead, Shares Climb

Longevity Health Holdings, Inc. - Common Stock

XAGE

Longevity Health Holdings Retains Nasdaq Listing To Complete Merger With 20/20 Biolabs

BayCom Corp (NASDAQ:<a href="https://www.benzinga.com/stock/BCML#NASDAQ">BCML</a>) ("BayCom" or the "Company"), the parent company of United Business Bank, today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on the Company's common stock, which represents a 33% increase (from $0.15 per share) in the Company's quarterly dividend. The dividend is payable on July 10, 2025 to shareholders of record as of the close of business on June 12, 2025.

Dividends

BCML

BayCom Board Hikes Quarterly Cash Dividend By 33% From $0.15 To $0.20 Per Share

Contracts

CVEO

Civeo Announces 3-Year Contract With A Metallurgical Coal Producer, Anticipates Contract Will Generate A$64M In Revenue Over 2025-2028 Contract Period

Ekso Bionics Holdings, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on June 2, 2025 on a split-adjusted basis under the existing symbol "EKSO". The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split.
Upon the effectiveness of the reverse stock split, the number of shares of the Company's outstanding common stock will decrease from approximately 35.5 million pre-split shares to approximately 2.4 million post-split shares, with no change in par value, per share.

Stock Split

EKSO

Ekso Bionics Reschedules 1-for-15 Reverse Stock Split To June 2, 2025

Graduating college might feel like stepping off a cliff. After years of lectures, finals, and ramen-fueled cramming sessions, the question hits hard: Now what? Billionaire Mark Cuban has a surprisingly chill answer—literally.
During a <a href="https://youtu.be/iuYFNu-UsrA?si=a38y4kR87bLSlGas">2019 BOLD TV interview</a> at the SALT Conference, the entrepreneur was asked what advice he'd give to young people, especially those stepping out into the real world for the first time.
"If I'm talking to somebody who's just <a href="https://www.benzinga.com/personal-finance/25/01/42932626/billionaire-mark-cuban-on-college-costs-pick-the-cheapest-school-you-can-find-its-about-learning-not-prestige">graduating from college</a>," Cuban said, "just say don't stress, right? You don't have to have all the answers. You don't have to have your chosen career. You don't have to know what you're going to be when you grow up. You don't have to be, you know, focused on adulthood. Just, you know, get a job. Just do something."
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Forget finding your life's calling by 22. Cuban's approach is refreshingly unpolished—because his own start was far from glamorous.
After graduating from Indiana University, he moved to Dallas. At night, he bartended. By day, he sold PC software—until he got fired from that too. So he leaned into what he could control.
"I <a href="https://www.benzinga.com/personal-finance/25/03/44314316/mark-cuban-loved-life-when-broke-eating-ketchup-sandwiches-and-sleeping-on-the-floor-with-5-roommates-but-says-rich-is-a-lot-more-fun">was pissant broke</a>, slept on the floor, got fired, was a shitty employee," he said. "Started the company, starved for a while, grinded it out, sold that company, used that money to buy and start another company, sold that company—partied like a rock star."
No apologies. No polishing the past. Just the reality of someone who figured it out by doing, not overthinking.
"I always knew I was an entrepreneur," he said, "but when I graduated from college in Indiana, I didn't know what I was going to do."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
"I'm just not employable," he joked. "So I started a company called MicroSolutions." It grew to 80 employees and pulled in $30 million in sales before he sold it. He used the money to buy a <a href="https://www.benzinga.com/news/24/10/41196856/heres-how-mark-cubans-drunken-splurge-of-125-000-turned-into-a-profitable-investment">lifetime pass on American Airlines</a>. "Traveled the world," he added, like that was just the natural next step.
But it wasn't luck or timing—it was curiosity and effort. "I was always trying to learn something new," he said. "Learning how to learn, to me, was the greatest skill that I got at Indiana."
That's the advice most people skip: learning is the job. Not knowing what you're doing? Totally normal. The trick is refusing to stay in that spot.
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
For anyone flirting with entrepreneurship, Cuban didn't downplay the process: "If you have to ask if you're ready, you're not ready," he said. "If you think it's all about raising money, you're not ready."
You'll get an idea, he said. You'll Google it. No one else has done it. You'll tell your friends and they'll say it's cool—and then you'll stop.
That's the line in the sand. Most people freeze there. "That's where you've got to put in the effort to learn what to do," Cuban said. "Can you make a prototype? Can you find one customer that's willing to pay you?"
The <a href="https://www.benzinga.com/personal-finance/25/05/45424979/billionaire-mark-cuban-doesnt-spend-money-on-a-housekeeper-and-buys-toothpaste-in-bulk-i-just-try-to-be-the-same-person-i-was-when-i-was-poor">advice wasn't glamorous</a>. But it was real. "You just grind it out," he said, "and typically, good things happen."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Mark Cuban Says You Don't Need To Have Life Figured Out By 22 — He Got Fired, Slept on the Floor, 'Partied Like A Rockstar,' And Still Became Rich

Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) has outperformed the market over the past 5 years by 7.49% on an annualized basis producing an average annual return of 21.76%. Currently, Hess has a market capitalization of $40.13 billion. 
Buying $100 In HES: If an investor had bought $100 of HES stock 5 years ago, it would be worth $267.65 today based on a price of $130.16 for HES at the time of writing.
<h3>Hess's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747859412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Hess Stock In The Last 5 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 54.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 33.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 31.39% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 25.71% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 23.35% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 22.35% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 19.30% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 18.52% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 8.85% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 6.86% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 6.32% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 5.21% at $0.39</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 4.62% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 4.43% at $1.61</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 3.70% at $1.34</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 3.31% at $0.06</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNGGF">Cann Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed down 98.46% at $0.0001</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 21.31% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 18.89% at $0.52</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 12.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 7.89% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 6.47% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 5.87% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 5.57% at $0.69</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 4.77% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 4.55% at $0.84</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 4.47% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 4.10% at $4.30</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed down 3.50% at $60.81</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 3.16% at $5.52</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed down 3.02% at $5.22</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BBRRF

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CLSH

CNBX

CNGGF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CWBHF

CXXIF

FFNTF

FUAPF

GNLN

GTBIF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

MRMD

NWVCF

OILFF

RMHB

SOLCF

TCNNF

TGIFF

UGRO

Marijuana Stock Movers For May 21, 2025

WIIM

WHLR

Wheeler Real Estate Investment Trust shares are trading lower after announcing a 1-for-7 reverse stock split.

Zoom Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) released its first-quarter results after Wednesday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/05/g45552065/zoom-communications-reports-financial-results-for-the-first-quarter-of-fiscal-year-2026"> from the quarter.</a>
The Details:&nbsp;Zoom reported quarterly earnings of&nbsp;$1.43&nbsp;per share which beat the analyst consensus estimate of&nbsp;$1.31. Quarterly revenue came in at&nbsp;$1.17 billion&nbsp;which met the Street estimate.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
At the end of the first quarter, Zoom reported the following customer metrics:
<ul class="wp-block-list">
<li>4,192 customers contributing more than $100,000 in trailing 12 months revenue, up 8% from the same quarter last fiscal year.</li>
<li>A trailing 12-month net dollar expansion rate for Enterprise customers of 98%.</li>
<li>Online average monthly churn of 2.8% for the first quarter, down 40 bps from the same quarter last fiscal year.</li>
<li>The percentage of total Online MRR from Online customers with a continual term of service of at least 16 months was 74.2%, up 40 bps year-over-year.</li>
</ul>
&#8220;We delivered another solid quarter, exceeding guidance in both revenue and profitability — a testament to the strength of our platform and AI-first innovation,&#8221; said Eric S. Yuan, Zoom&#8217;s CEO. 
&#8220;In an uncertain macro-economic environment, customers are turning to Zoom to drive efficiency, improve customer and employee experiences, and future-proof their businesses,&#8221; Yuan added. 
Outlook:&nbsp;Zoom raised its fiscal 2026 adjusted EPS guidance from $5.34 to $5.37&nbsp;to&nbsp;$5.56 to $5.59, versus the $5.41&nbsp;analyst estimate, and raised its revenue outlook&nbsp;from&nbsp;a range of $4.79 billion to $4.79 billion&nbsp;to&nbsp;a new range of $4.8 billion to $4.81 billion, versus the&nbsp;$4.79 billion&nbsp;estimate.
ZM Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Zoom stock was up 1.74% at $83.70 after-hours Wednesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Image: Shutterstock

After-Hours Center

Tech

Zoom Stock Climbs After Better-Than-Expected Q1 Results, Raised FY Guidance

VIGL

Trading Halt: Halted at 4:25:00 p.m. ET - Trading Halt: Halt News Pending

CLRO

ClearOne shares are trading lower after the company announced a 1-for-15 reverse stock split.

The authorization in Australia is for adult patients who are Apolipoprotein E-ε4&nbsp;heterozygotes or non-carriers
INDIANAPOLIS, May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in adults who are Apolipoprotein E ε4 (ApoE ε4)&nbsp;heterozygotes or non-carriers. Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed.
Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. Kisunla can help remove the excessive buildup of amyloid plaques and help slow the cognitive and functional decline in patients with early symptomatic Alzheimer's disease.

Biotech

Global

General

Eli Lilly & Co Announces Kisunla (Donanemab) Receives Marketing Authorization In Australia For The Treatment Of Early Symptomatic Alzheimer's Disease

Shares of Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), a U.S. electric vehicle maker, fell 7% to $2.75 on Wednesday afternoon, as rising long-term Treasury yields shook investor confidence in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45550679/treasury-yields-top-5-these-20-stocks-tanked-in-just-one-hour">high-growth</a> companies.
What To Know: Lucid, like many speculative growth stocks, is sensitive to interest rate changes because higher yields reduce the present value of future earnings, making such stocks less attractive.
The sell-off followed a <a href="https://www.benzinga.com/government/regulations/25/05/45550324/us-bond-market-flashing-red-30-year-yield-tops-5-prices-tank-to-october-2023-lows">disappointing</a> 20-year U.S. Treasury bond auction, which signaled weak investor demand and sent yields soaring. The 30-year yield jumped to 5.08%, the highest since October 2023, while the iShares 20+ Year Treasury Bond ETF sank to 19-month lows.
Investor unease deepened due to fears over rising deficits tied to President Donald Trump's proposed $4.1 trillion tax cut plan, now under debate in Congress. The plan <a href="https://www.benzinga.com/government/regulations/25/05/45550324/us-bond-market-flashing-red-30-year-yield-tops-5-prices-tank-to-october-2023-lows">could add</a> to long-term fiscal pressure, forcing yields even higher.
With higher bond yields undermining appetite for risky assets, the market saw broad declines in tech and EV stocks. Unless bond demand improves or inflation eases, rate-sensitive names like Lucid may continue to struggle.
<h1 class="wp-block-heading">How To Buy LCID Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, Lucid is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Lucid has a 52-week high of $4.43 and a 52-week low of $1.93.
Read Also: • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45544593/hedge-funds-are-building-a-towering-wall-of-bets-against-stocks">Hedge Funds Are Building A Towering Wall Of Bets Against Stocks</a>
Photo: Lucid Motors

LCID

Lucid Group (LCID) Stock Falls Amid Surging Treasury Yields: What's Going On?

DOMO

Domo shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 guidance.

NVTS

Navitas shares are trading higher after NVIDIA selected the company to collaborate on 800 V HVDC architecture.

<a href="https://www.globenewswire.com/Tracker?data=8gb146X1fgj4rHLdmOjihkTvLBnNbi3jTt8DTKUQTJx1Y83kCtgbovf6tBNxKWjmDfe1l5HuhTVV8ivaQKTa0hxkXTy7iLvGFJZ8_1f6jN4=">Navitas Semiconductor</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>), the industry leader in next-generation GaNFast&#x2122; gallium nitride (GaN) and GeneSiC&#x2122; silicon carbide (SiC) power semiconductors, today announced a collaboration with <a href="https://www.globenewswire.com/Tracker?data=6pxDnue745qtQFfDK1Bb5nJkjxrKd8cM9aqmOQs2osE4UMwIoSQq6wwuM5gYkdUHdIsTf7JuaysWnOk9zKfO2Q==">NVIDIA</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) on their next-generation 800 V HVDC architecture to support ‘Kyber' rack-scale systems powering their GPUs, such as Rubin Ultra, enabled by GaNFast&#x2122; and GeneSiC&#x2122; power technologies.
NVIDIA's next generation of 800V DC architecture aims to establish high-efficiency, scalable power delivery for next-generation AI workloads, to ensure greater reliability, efficiency, and reduced infrastructure complexity.

NVDA

Navitas Semiconductor Collaborates With NVIDIA On Next-Gen 800V HVDC Architecture Using GaNFast And GeneSiC Technologies To Power AI Systems Like Rubin Ultra

Sable Offshore shares are trading lower after the company announced a $200 proposed public offering.

Equitable Holdings Announces That It Will Increase Its Quarterly Common Stock Dividend From $0.24/Shr To $0.27/Shr

<ul>
<li>Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancer</li>
<li>Presentation of data at the European Lung Cancer Conference in a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) in locoregional recurrent NSCLC and a Phase 1 study of JNJ-1900 (NBTXR3) in combination with nivolumab or pembrolizumab for patients with lung metastases from NSCLC or other solid tumors</li>
<li>Strengthened financial position through an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) which extended cash runway into mid-2026 and permanently reduced operational cash burn</li>
<li>€39.8 million in cash and cash equivalents as of March 31, 2025</li>
</ul>
PARIS and CAMBRIDGE, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=27FXeQkkE_XtGds2LIUZDF-7t_GRIPBQO4wdlgdCIIytv7ouQ-76BiDCVVl--RPfSm9zjywh6BVBJeuljbCLsg==">NANOBIOTIX</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first quarter of 2025.

NBTX

Nanobiotix Provides Q1 2025 Operational Update; Says It Anticipates That The Cash And Cash Equivalents Of €39.8 Million As Of March 31, 2025, Will Fund Its Operations Into Mid-2026

H2O Retailing

Comments

H2O Retailing

H2O Retailing (HTOCF) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル